Otezla is currently approved only for moderate ... (risankizumab), as well as side effects of other therapies like topical corticosteroids. Dermavant's phase 3 trials of tapinarof – PSOARING ...

For that reason, topical steroids aren't recommended for sensitive ... notably from Amgen's oral PDE4 inhibitor Otezla (apremilast). Otezla – which Amgen acquired for $13.4 billion in 2019 ...